In line with this our studies employing syngenic mice model of breast cancer reveal that simultaneous administration of anti-Eotaxin or anti-Oncostatin M antibody greatly increases the efficacy of anti-angiogenic drug Bevacizumab. This evidence concerns the gene CCL11 and breast cancer.